Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Tango Therapeutics Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 4 distinct art units, showing that the portfolio’s prosecution activity spans multiple examination channels.
LADD, CAROLYN LOUISE is the busiest examiner, with 2 pending matters. Counsel can address that examiner’s files as a shared strategic group, while treating the other matters according to their separate art-unit assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LADD, CAROLYN LOUISE | 2 | 58.6% | +47.1% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833468 | COMPOUNDS AND METHODS OF USE | LADD, CAROLYN LOUISE | — |
| 18833315 | COMPOUNDS AND METHODS OF USE | LADD, CAROLYN LOUISE | — |
| 18833319 | COMPOUNDS AND METHODS OF USE | ROZOF, TIMOTHY R | — |
| 18740064 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1622 | 1 |
| 1625 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833468 | COMPOUNDS AND METHODS OF USE | LADD, CAROLYN LOUISE | 1629 | §112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18833315 | COMPOUNDS AND METHODS OF USE | LADD, CAROLYN LOUISE | 1622 | §112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18833319 | COMPOUNDS AND METHODS OF USE | ROZOF, TIMOTHY R | 1625 | §112DP | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18740064 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | ANDERSON, REBECCA L | 1626 | DP | Non-Final OA | — | Pending | Jun 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTango Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 3 examiners.
Carolyn Louise Ladd has the most, with 2 of Tango Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
